CLOSED

GET A PIECE OF IMETABOLIC BIOPHARMA

Bringing Hope to Communities Through Tech-Powered Biopharma

iMetabolic Biopharma Corporation (iMBP) is an early-stage drug discovery company innovating at the intersection of technology and biotechnology to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones. Currently, we are pre-market, advancing five different disease asset programs, and in the process of developing a proprietary technological platform for the discovery of more effective and less expensive drugs. This will allow us to continuously expand our drug pipeline while increasing company value.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$360,197.44 Raised

REASONS TO INVEST

Our technology-powered iPlatform™ pipeline removes the roadblocks that typically make drug development slow, expensive, and inefficient, with the aim to put lifesaving treatments in the hands of communities everywhere.

Our revolutionary approach to drug development has already landed us three strategic technology and pharma industry partnership deals, five disease therapeutic asset programs already in motion, and four additional programs prepared to go online.

We are led by a passionate and highly talented team who understands the human nature of the work we do. We are determined to apply our collective knowledge and experience to bring hope, empowerment, and opportunity to our investors and their communities.

TEAM

Urban Austin Kiernan • Founder, Chairman, CEO, President, and Treasurer

With over 22 years of industry business and research experience, Dr. Urban A. Kiernan is the Founder, Chairman and CEO of iMetabolic Biopharma Corporation (iMBP). Under his leadership iMBP has raised >$1.1 Million in startup investment, established two partnership deals with Ligand Pharmaceuticals/OmniAb, and an additional partnership with Amazon Web Services. These partnerships have paid off with dividends as they have led to the establishment of both the iPlatform™ and a drug asset pipeline towards five different disease programs. Doing more with less is Dr. Kiernan’s business philosophy. Prior to starting iMBP, Dr. Kiernan was the Director of Biomarker Discovery at Intrinsic Bioprobes Inc, during which time he was the recipient of ~$4 Million in Phase I & II National Institutes of Health grants, negotiated significant licensing and service deals with companies such as Johnson & Johnson and Promedior, and was able to achieve his first business exit through acquisition. He then later worked for Thermo Fisher Scientific and was able to quickly rise through the ranks into Global Business Development, providing him a breadth of knowledge and experience in the life science and biopharma sectors. He received his M.Sc. and Ph.D. from Arizona State University, is a devoted husband, father and Jiu Jitsuka. He has authored more than 45 peer reviewed publications, 4 book chapters and received 11 patent awards…and there is still more to come!!!

Stephen Adam Munk • Interim - COO and Board Director

Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts. He received his B.S. degree in chemistry at ASU, and then earned his Ph.D. in organic synthesis at The University of California at Berkeley. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager.

David F Hendren • Chief Business Officer

David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, life science, biomedical technology, digital health, and related technology and service areas. He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has launched successful medical technologies from inception, and led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions cumulatively exceeding $1B. In operating, board, and advisory roles, David has been central to identifying opportunity, building teams, formulating strategy, securing capital, developing business and strategic alliances, and driving successful exits to harvest value for stakeholders. He earned his AB at Dartmouth College and his JD at Northwestern University Pritzker School of Law.

the pitch

At iMBP, we are the next stage of biotech evolution. We are combining innovative technology with biotechnology as part of our proprietary, cutting-edge “TechBio” approach to biopharma. We give communities the opportunity to invest in their own health as we improve the way drugs are discovered to make them more effective and affordable. We have strategic partnerships in place and drug candidates in development in our key markets of metabolic, cardiovascular, and neurodegenerative diseases. The company is pre-revenue and in the prototype phase.

Overview

Bringing Hope to Communities Through Tech-Powered Biopharma

iMBP is developing a revolutionary approach to drug discovery to help people live longer, healthier, and happier lives with their loved ones. Our founder, Chairman, and CEO Dr. Urban A. Kiernan, Ph.D. is a seasoned BioTech leader with decades of industry business and scientific research experience. However, his passion is what drives him beyond what any academic or work experience could ever afford him.

"The feeling of helplessness I experienced when my first wife died from cancer was devastating. Then, a single Dad with two little girls, the world turned upside-down. From this pain, I recognized the utopic potential the biopharma industry has to offer... and that is the power to keep families together... for just one more... one more memory to hold onto. You cannot put a price tag on that. This is my passion and this is why I created iMBP."

– Dr. Urban A. Kiernan –

Husband, Father, Founder & CEO of iMBP

The Problem & Our solution

Harnessing the Power of TechBio to Improve Drug Discovery & Development

Today’s developmental process for new, lifesaving drugs is complex, expensive, and time-consuming. The current industry solution is to simply spend more money, resulting in over-expensive therapeutics with marginal benefits. Ultimately, the deficiencies of this system places the cost burden on the people who need these therapeutic solutions most.

Our Solution was the development of iPlatform™, our proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably. This is the value that TechBio offers to you and your loved ones. Enabled through our partner Amazon Web Services (AWS), iPlatform™ is rapidly evolving and already producing drug asset leads for the expansion of the iMBP drug pipeline.

the market & Our Traction

Rapid Development & Progress in Multiple Massive Markets

Our drug asset efforts are currently focused in three primary areas: metabolic disease, cardiovascular disease, and neurodegenerative disease (Alzheimer’s Disease).

Source | Source

Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life, including:

Two partnership agreements with Ligand Pharmaceuticals/OmniAb for drug asset development
A partnership agreement with Amazon Web Services (AWS) for iPlatform™ development
Acceptance of iMBP into the McDermott Wills and Emory LEAP program for corporate legal counsel
Raised over $1,100,000 in total funding to date
An issued U.S. patent for proprietary therapeutic methodology (US/9,783,600)
Five established disease therapeutic asset programs, with four additional programs in preparation to go online
Preparation of first technology and two additional method IP set for provisional filing in December 2022
Assembled group of world renowned and experienced advisors and executive team members

Source | Source

"Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance."

– John Higgins –

CEO at Ligand Pharmaceuticals

Why Invest

A Brighter Future for Drug Development

Through this raise, we offer communities the opportunity to directly invest in solutions for their own health.

BioTech investment opportunities are typically reserved for an elite circle of the same investors, and we are eager to break this cycle by sharing with you our unique equity crowdfunding campaign.

With major partnerships in place and multiple drug candidates already in development, we are ready to change the way we care for our communities and hope to give loved ones and families as much time together as possible. Invest in iMBP today and become a part of this unique opportunity with us.

ABOUT

HEADQUARTERS

2155 E Conference Dr STE 115
Tempe, AZ 85284

WEBSITE

View Site

iMetabolic Biopharma Corporation (iMBP) is an early-stage drug discovery company innovating at the intersection of technology and biotechnology to develop new, life-saving drugs to fight against some of today's most devastating chronic diseases affecting our loved ones. Currently, we are pre-market, advancing five different disease asset programs, and in the process of developing a proprietary technological platform for the discovery of more effective and less expensive drugs. This will allow us to continuously expand our drug pipeline while increasing company value.

TERMS

iMetabolic BioPharma

Overview

INTEREST RATE

3.5%

MATURITY DATE

Dec 31, 2024

DEADLINE

Jul. 7, 2023 at 6:59 AM UTC

VALUATION CAP

$25M

FUNDING GOAL

$10K - $1.23M

Breakdown

MIN INVESTMENT

$250

DISCOUNT

10.0%

CONVERSION TRIGGER

$5,000,000

OFFERING TYPE

Convertible Notes

TYPE OF EQUITY

Preferred Stock

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$4,601

$64,248

Cash & Cash Equivalents

$4,601

$64,248

Accounts Receivable

Short-Term Debt

Long-Term Debt

$161,025

$155,471

Revenue & Sales

Costs of Goods Sold

Taxes Paid

Net Income

-$94,513

-$63,745

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

A convertible note offers you the right to receive Preferred Stock in iMetabolic BioPharma. The amount of Preferred Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $5,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 10.00% discount on the price the new investors are paying. You also receive 3.50% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Preferred Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).

*Annual Interest Rate subject to adjustment based on bonuses below.

Loyalty Bonus | 5% Bonus

As you have previously invested in iMetabolic BioPharma, you are eligible for additional bonus interest.

Time-Based:

Visionary

Invest within the first 72 hours and receive 15% bonus interest.

Disruptor

Invest within the first week and receive 10% bonus interest.

Innovator

Invest within the first two weeks and receive 5% bonus interest.

Amount-Based:

$500+ | Knight

Invest $500+ and receive + 5% bonus interest.

$1,000+ | Baron

Invest $1,000+ and receive + 7% bonus interest.

$5,000+ | Duke

Invest $5,000+ and receive + 10% bonus interest + a Membership to the Exclusive iMBP VIP Forum.

$10,000+ | Prince

Invest $10,000+ and receive + 15% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.

$20,000+ | Emperor

Invest $20,000+ and receive + 20% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonuses from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

iMetabolic BioPharma will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 3.85% instead of 3.5%.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Loyalty Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.

ALL UPDATES

12.16.24

Wrapping Up 2024 for iMBP

During this holiday season, we extend warm wishes to you and your loved ones. As we look back on the past year, we at iMetabolic Biopharma are proud to be at the forefront of a medical revolution.

Our mission is clear: to tackle the growing crisis of obesity-related comorbidities head-on. We're pioneering the future of healthcare with our groundbreaking TechBio AI technology, a tool with the potential to revolutionize the field. This proprietary approach doesn't just enhance the discovery and development of therapeutics—it redefines them.

Your support is crucial as we transform the landscape of medicine, one innovative solution at a time. Visit our website to sign up for our newsletter to follow our developments and latest news. We invite you to follow us on social media to stay informed about our innovative solutions. May your holidays be filled with joy, love, and good health for you and your families.

If you have not been following the company since the close of the campaign, there have been significant advancements made. We have included selected 2024 highlights below.

📢 iMetabolic Biopharma Corporation (iMBP) has received its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH)

We are excited to share that iMetabolic Biopharma Corporation (iMBP) has received its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). This Phase 1 grant, which is funded by the National Heart, Lung, and Blood Institute (NHLBI), will support our innovative drug program aimed at treating atherosclerotic cardiovascular disease (ASCVD), a leading cause of heart attacks and strokes. Our use of the iPlatform™ technology has allowed us to develop a pipeline of promising drug candidates. One of these candidates, the iMBP-001 asset, is a new multidomain recombinant fusion protein that offers unique therapeutic specificity and a novel approach focusing on reducing lipoprotein particles. Dr. Urban Kiernan, our founder and CEO, emphasizes the urgent need for innovative strategies in the treatment of cardiovascular diseases, particularly as the obesity epidemic continues to escalate. Traditional cholesterol-lowering treatments have proven insufficient in tackling this complex issue, which is why we are excited about the potential of our therapeutic innovations, especially with the backing of this NIH grant.

We encourage you to visit Yahoo Finance and read the full press release to delve deeper into our groundbreaking efforts. This ongoing momentum not only enhances the iMBP mission but also positions us as a key player in the investor community.

As we continue to forge new paths, we invite you to join us on this transformative journey that promises to advance health outcomes and create significant value for our stakeholders.

The Decoding Health Podcast with Dr. Urban A. Kiernan

Dr. Kiernan pledged any views of this episode on YouTube to be donated to the Hundley Foundation.

As a part of iMBP’s 2024 outreach campaign, Dr. Kiernan has launched the Decoding Health Podcast which airs new episodes every Monday and Thursday of each week. You may initially question the value of such a media presence however, it allows Dr. Kiernan to highlight science, key team and community members, and participate in cause-based community action. The Decoding Health Podcast was fortunate to have Mr. Brett Hundley in for an interview. A UCLA Bruins superstar who spent 8 seasons in the NFL, Brett has now turned entrepreneur, but more importantly, is the Chairman of the Hundley Foundation. This is a charitable organization to help epilepsy patients and their families. Brett discusses the struggle his family endured and how the creation of the Hundley Foundation can make a positive impact.

Please help by making this episode go viral. This is the easiest donation you will ever do. Just Subscribe to the Decoding Health Podcast, watch the episode (even if only in part), and tell your friends. I hope this episode enhances awareness of this terrible disease.

iMBP in Health and Wellness

Also through the Decoding Health Podcast, Dr. Kiernan has been able to highly his knowledge base and expertise in other industries. He appeared on the IGNITE Coaching Series by Coach360, a premier health and wellness education brand taking the fitness market by storm. With the explosion of the use of Wegovy and Zepbound for weight loss, Dr. Kiernan participated on the IGNITE Coaching Series by Coach360 back in September where he weighed in on the drug’s modes of action, areas of clinical success, and concerns to watch for in the future.

As iMBP’s proprietary multi-domain recombinant fusion protein class of therapeutics have a bioactive mimetic peptide component, Dr. Kiernan is becoming more widely recognized as a leader in the field to provide an unbiased education as to how these new weight loss drugs will impact the health and wellness field as well as society as a whole.

iMBP in the News

We are honored to share that iMBP was featured in the Venture Beat alongside several other inspiring startup companies that are making a difference today.

The VentureBeat is a high-profile investor publication that shows that iMBP is getting noticed. We have also issued our press release formally announcing our second NIH SBIR grant award. Featured in Yahoo Finance, this announcement is being seen by thousands of readers around the world. Again, slowly but surely the iMBP story is building within the investor community. Read the article.

Visit our website to sign up for our monthly newsletter to follow our developments and latest news.

07.07.23

Thank you to all our investors! Over $367K raised!

Our sincere thanks to those individuals and groups that have invested in our mission to improve the way drugs are discovered, making them more effective and affordable.

Hear from the founder and CEO of iMBP, Dr. Urban A. Kiernan

Even though our campaign has ended, we want our investors to stay informed. Sign up for updates on the latest iMBP news and events, and see the progress iMBP is making in the biopharma industry!

Sign Up Here

Thank you!

The iMBP Team

07.06.23

Only a few hours left to invest in iMBP

Hello iMBP community!

Time is running out! With just a few hours left, seize the opportunity to invest in iMBP. We are on a mission to be the next stage in developing a revolutionary approach to drug discovery and developing more advanced therapeutic solutions.

Together, we can give communities the opportunity to invest in their own health as we improve how drugs are discovered to make them more effective and affordable.

Only a few hours left to invest Warmest regards,

Dr. Urban A. Kiernan

Found and CEO

iMBP

07.06.23

Last chance - campaign ends in 24 hours Invest In iMBP Today!

Hello iMBP community,

Wow, time has flown! Our campaign ends in 24 hours but there’s still time for you to invest in iMBP.

This is your last chance to join the biopharma revolution and make an impact on how drugs are discovered, making them more effective and affordable.

24 hours left to invest - Join the iMBP community by becoming an owner! Thank you,

Dr. Urban A. Kiernan

Found and CEO

iMBP

07.05.23

Just 2 Days Left to Invest In iMBP

Hello iMBP supporters,

Don't let this opportunity slip away! iMBP is in its final phase, and you have just 2 days left to invest and become a valued shareholder. Together, we can revolutionize the drug discovery and therapeutics in cardiovascular disease, Alzheimer’s and type 2 diabetes.

Warmest regards,

Dr. Urban A. Kiernan

Found and CEO

iMBP

07.04.23

Happy Independence Day from the iMBP Team

Dear iMBP Community,

On behalf of the entire iMBP team, allow me to wish each and every one of you who lives in the United States of America a Safe and Happy Independence Day.

Please take this moment to share time with your loved ones and make memories to last a lifetime. You cannot put a price tag on that.

Warmest Regards,

Urban A. Kiernan and the rest of the iMBP Team

07.03.23

iMBP is just $50K away from hitting $400K! 3 days left to invest.

iMBP is $50K away from $400K raised! Help us reach our goal and close out our campaign strong.

You have 3 days to invest in a revolutionary company that is pushing boundaries in the biopharma space. For just $250, you can become an early owner!

Our campaign ends in 3 days. Invest today!

Warmest regards,

Dr. Urban A. Kiernan

Found and CEO

iMBP

07.02.23

The countdown is on - Invest in iMBP

Hello iMBP community!

We are in the last few days of our campaign. Here is a message from me spelling out the future direction of iMBP’s fundraising efforts and a personal invitation to all our followers to seize this opportunity while it lasts.

Together, we can make a difference in improving the treatment of disease. So, what are you waiting for? – join the community by becoming an owner!

Thank you,

Dr. Urban A. Kiernan

Found and CEO

iMBP

06.30.23

6 days left to invest!

Hello iMBP community!

We have 6 days left of our crowdfunding campaign.

WOW! Where did the time go? This year would not have been possible without amazing investors like you!

There are 6 days left of our crowdfunding campaign, and you can become an investor in iMBP for only $250. We are entering a brand-new era of revolutionizing the biopharma space!

We hope you'll join us on this journey! If you want to help us complete this extraordinary campaign, now is the time!

Please share our raising page with your network, encourage them to invest, and help transform the drug discovery process.

Dr. Urban A. Kiernan

Founder and CEO

iMBP

06.29.23

Closing soon!! 1 week to invest in iMBP.

There are just 7 DAYS left to become an official part-owner in the biopharma revolution.

Here at iMBP, we are on a mission to develop new, life-saving drugs to fight against Alzheimer’s disease, cardiovascular disease and type 2 diabetes.

Our campaign is closing in 1 week. Invest before the campaign ends!

Warmest regards,

Dr. Urban A. Kiernan

Found and CEO

iMBP

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.

10%

Stack Venture Club & Rewards!

Members get an extra 10% interest rate in addition to rewards below!

Venture Club

Venture Club Members earn 10% bonus interest rate on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

$500

Knight

Invest $500+ and receive + 5% Bonus.

$1,000

Baron

Invest $1,000+ and receive + 7% Bonus.

$5,000

Duke

Invest $5,000+ and receive + 10% Bonus + a Membership to the Exclusive iMBP VIP Forum.

$10,000

Prince

Invest $10,000+ and receive + 15% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.

$20,000

Emperor

Invest $20,000+ and receive + 20% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.

JOIN THE DISCUSSION

0/2500

Jarod Rudisill

5 months ago

Hi, I have received zero updates since investing. Would love an update. I'm sure all other investors would like one as well.

Urban Kiernan

iMetabolic BioPharma

•

2 years ago

Hello iMBP Community! As you have seen, we have extended our campaign. Any iMBP investor who has a current Pending order needs to reconfirm their order. This is a regulatory requirement. This is time sensitive as all orders not reconfirmed by March 22nd will be cancelled. Here is a message from me explaining all of this in more detail. https://youtu.be/NdtDy7Mnaik Thank you for your attention in this matter and we look forward to continuing to grow with all of you. Best, Urban

Jarod Rudisill

2 years ago

Thank you for your previous replies. I just have one final question. What is the exit strategy and what kind of time frame and valuation can be expected?

Jarod Rudisill

2 years ago

Do you see DeepMind and Alpha Fold as a competitor and if so how do you plan to compete with a much better funded peer?

Jerry Irwin

2 years ago

good news---March 16th gives me time to participate (hope you're working on something for small vessel disease which runs in my family)

Jerry Irwin

2 years ago

when will your raise end?

Jarod Rudisill

2 years ago

Is my understanding correct that you use ML to discover therapies? And do you plan on licensing out therapies once you discover them or bringing them to market on your own? Also, do you plan on letting other companies use iMPB and taking a percentage of revenue they generate or something like that?

DAVID david.l.porter@sbcglobal.net

2 years ago

Where can I find the Form 6 ?

Jason Varso

2 years ago

Good afternoon, I'm considering investing. I'm curious on other diseases that you are looking into to help cure/sustain, like Parkinson's and P.S.P. (Progressive Supranuclear Palsy). My Dad passed away from P.S.P. recently and I worked with a well-known actor who's wife has had Parkinson's for over 20 years along with Michael J. Fox. Are these two areas also being looked into? It's imperative that we find what's causing these diseases and curing them. Another one to look into is Leptomeningeal Carcinomatosis, which took my girlfriend back in 2017. It was her 4th type of cancer that she endured. Thank you in advance for answering my questions. ~ Jason

Brooke Pride

2 years ago

I saw that iMBP applied to two NIH grants for Alzheimer's Disease. Could you explain to me how this helps the company. Are these loans, like SBA? Are they investments? Sorry for not fully understanding, but this is the first biotechnology investment I have ever considered.

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

How much can I invest?

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.

When will I receive my shares?

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

What will the return on my investment be?

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

Can I cancel my investment?

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.

What is the difference between Regulation Crowdfunding and Regulation A+?

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

More FAQs

RAISED

$360,197.44

INVESTORS

275

MIN INVEST

$250

VALUATION CAP

$25M

Get To Know Us

Our Team

Careers

Blog

Let's Work Together

Raise Capital

Refer a Founder, earn $10k

Success Stories

Partnerships

Need Help

Help Center

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Disclaimer

Annual Reports

Form CRS

Reg. BI Disclosure

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.